Form 4: Revvity Executive Joel Goldberg Reports Stock Transactions

Joel Goldberg, a Revvity executive, reported the acquisition and disposal of company stock and stock options related to tax obligations and vesting schedules.

Summary

• On February 4, 2025, Joel Goldberg, a Senior Vice President at Revvity, surrendered 650 shares of common stock to cover tax obligations related to vesting restricted stock at a price of $123.69 per share.
• Goldberg also acquired 4,939 shares of time-based restricted stock units that are scheduled to fully vest on the third anniversary of the grant date.
• Additionally, Goldberg was granted 13,656 non-qualified stock options with an exercise price of $123.35, vesting in three equal annual installments starting February 4, 2026, and expiring on February 4, 2032.
• Following these transactions, Goldberg directly owns 37,689 shares of common stock and indirectly owns 63,709 shares through the Goldberg Irrevocable 2021 Trust.
• He also directly owns 13,656 derivative securities in the form of non-qualified stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation and tax obligations, with no indication of unusual or concerning activity.

Positives

• The granting of restricted stock units and stock options to Goldberg suggests continued investment in the company's future by its executives.
• The vesting schedule of the stock options and restricted stock units incentivizes long-term performance.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules of the restricted stock units and stock options suggest a multi-year commitment from the executive.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the technology and life sciences industries, used to align management's interests with those of shareholders.
• Vesting schedules of three years for RSUs and annual installments for options are typical in the industry, similar to companies like Thermo Fisher Scientific or Danaher Corporation.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they primarily reflect internal compensation adjustments.
• Shareholders may view the stock option and RSU grants as a positive sign, aligning management's interests with long-term value creation.

Key Dates